(Q45268057)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19124424%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

editorial

0 references

title

ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19124424%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19124424%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1

Christoph Schindler

1 reference

11 December 2017

1 August 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19124424%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic advances in cardiovascular disease

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19124424%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19124424%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19124424%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

233-248

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19124424%20AND%20SRC:MED&resulttype=core&format=json

Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Update on the role of the AT2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Renin-angiotensin system as a therapeutic target in managing atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Increase in systemic blood pressure during intra-arterial PD123319 infusion: evidence for functional expression of angiotensin type 2 receptors in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Renal failure and ACE inhibition: how much is too much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Dose-response relationships with antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Angiotensin II: one driving force behind atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Forearm vasodilator response to angiotensin II in elderly women receiving candesartan: role of AT(2)- receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

The effects of candesartan on vascular responses to angiotensin II and norepinephrine in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

The role of the renin-angiotensin system in the development of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Mechanisms of angiotensin II formation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Pathophysiological regulation of the AT1-receptor and implications for vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Deoxycorticosterone acetate salt hypertension in apolipoprotein E-/- mice results in accelerated atherosclerosis: the role of angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708094309